What's The Big Deal About Gene Editing? Drug Development.

What's The Big Deal About Gene Editing?  Drug Development.

Gene editing technology is fueled by two things - the need for better, more effective drug development, and the creation of a new technology called CRISPR. The old way to attack disorders have included transplantation to replace hematopoietic stem cells or gene therapy yield normal copies of the affected gene in cells through expression. Now the focus is genomes. CRISPR systems offer tremendous flexibility and power, and are opening up opportunities. That opportunity, seen in the chart here, is most present in drug development.


Affymetrix Acquisition Deepens and Complements Thermo Fisher’s Existing Product Groups in Clinical Molecular Testing, Translational Research, Flow Cytometry and Applied Testing

Affymetrix Acquisition Deepens and Complements Thermo Fisher’s Existing Product Groups in Clinical Molecular Testing, Translational Research, Flow Cytometry and Applied Testing

Kalorama Information offers additional analysis of the markets discussed below with an upcoming title on clinical and research microarrays as well as published reports including The Market for Prenatal, Newborn and Carrier Genetic Testing , The World Market for Cancer Diagnostics, 6 th Ed. , Proteomics Research Markets , The World Market for Flow Cytometry in IVD Applications , and The World Market for Veterinary Diagnostics.

Thermo Fisher Scientific’s reach in the global life sciences market ...


Ariosa Matches Sequenom-Illumina with NIPT LDT Licensing Move

Following the agreement between Sequenom and Illumina earlier this year allowing the latter to license pooled non-invasive prenatal testing (NIPT) IP to third-party labs worldwide, Roche Diagnostics’ Ariosa Diagnostics announced this week that it would grant licenses to labs for its own technology relating to NIPT. The three major players in prenatal testing operate their own labs to perform NIPT services on sent-out samples, but have encouraged outside labs to adopt their technologies in order ...


Carrier, Prenatal and Pediatric Genetic Testing Still a Big Draw for Investors and Labs

Carrier, Prenatal and Pediatric Genetic Testing Still a Big Draw for Investors and Labs

Genetic testing for inherited diseases has been a volatile industry space in recent years headlined by Myriad Genetics’ hold over BRCA testing and the subsequent opening of that market to competition with a 2013 Supreme Court ruling. Outside of testing for patient testing for oncology risk, a significant component of genetic testing is reproductive health-oriented testing for carrier genes and prenatal conditions. Atop the high-growth market for non-invasive prenatal testing (NIPT) are Sequenom ...